The IL-33/ST2 pathway: therapeutic target and novel biomarker

Nat Rev Drug Discov. 2008 Oct;7(10):827-40. doi: 10.1038/nrd2660.

Abstract

For many years, the interleukin-1 receptor family member ST2 was an orphan receptor that was studied in the context of inflammatory and autoimmune disease. However, in 2005, a new cytokine--interleukin-33 (IL-33)--was identified as a functional ligand for ST2. IL-33/ST2 signalling is involved in T-cell mediated immune responses, but more recently, an unanticipated role in cardiovascular disease has been demonstrated. IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast-cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.

Publication types

  • Review

MeSH terms

  • Animals
  • Atherosclerosis / etiology
  • Atherosclerosis / metabolism
  • Biomarkers / metabolism
  • Disease Progression
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Humans
  • Interleukin-1 Receptor-Like 1 Protein
  • Interleukin-33
  • Interleukins / agonists
  • Interleukins / antagonists & inhibitors
  • Interleukins / metabolism
  • Interleukins / physiology*
  • Receptors, Cell Surface / agonists
  • Receptors, Cell Surface / antagonists & inhibitors
  • Receptors, Cell Surface / metabolism
  • Receptors, Cell Surface / physiology*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*

Substances

  • Biomarkers
  • IL1RL1 protein, human
  • IL33 protein, human
  • Interleukin-1 Receptor-Like 1 Protein
  • Interleukin-33
  • Interleukins
  • Receptors, Cell Surface